| Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol. | |
| | |
MedLine Citation:
|
PMID: 17122799 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The cardiovascular benefits of therapy with the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are well documented. Undertreatment of dyslipidemia remains pervasive, however, and the introduction of more-aggressive optional LDL-cholesterol targets in US guidelines only heightens the challenges of reaching the target values. Combination therapy with a statin and the cholesterol absorption inhibitor ezetimibe could help in the management of patients who have an inadequate reduction in cholesterol after making changes to lifestyle or taking statins alone. The effects of the combination on cardiovascular risk remain speculative, however, and clinical trials are in development. In this Review we consider the rationale for combination therapy in the context of achieving LDL-cholesterol goals. |
| | |
Authors:
|
Antonio M Gotto; John A Farmer |
Related Documents
:
|
18794729 - Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1... 15251559 - Treatment of dyslipidemias. 12069369 - Future directions in lipid therapies. 10710119 - Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemi... 12679839 - The role of 24s-hydroxycholesterol in alzheimer's disease. 12628479 - Statin effects on cholesterol micro-domains in brain plasma membranes. 12223429 - Dietary correlates of plasma insulin-like growth factor i and insulin-like growth facto... 16979329 - Short-term, increasing dietary protein and fat moderately affect energy expenditure, su... 9200239 - Diphasic allometric growth of body components in white leghorn pullets fed ad libitum a... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Nature clinical practice. Cardiovascular medicine Volume: 3 ISSN: 1743-4300 ISO Abbreviation: - Publication Date: 2006 Dec |
Date Detail:
|
Created Date: 2006-11-23 Completed Date: 2006-12-15 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 101226507 Medline TA: Nat Clin Pract Cardiovasc Med Country: England |
Other Details:
|
Languages: eng Pagination: 664-72 Citation Subset: IM |
Affiliation:
|
Weill Medical College of Cornell University, 445 East 69th Street, OH205, New York, NY 10021, USA. amg_editorial@med.cornell.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticholesteremic Agents
/
pharmacology,
therapeutic use* Azetidines / pharmacology, therapeutic use* Cardiovascular Diseases / blood, etiology, prevention & control* Cholesterol, LDL / blood* Drug Therapy, Combination Dyslipidemias / blood, complications, drug therapy* Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology, therapeutic use* Lipid Metabolism / drug effects Practice Guidelines as Topic Randomized Controlled Trials as Topic Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Azetidines; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 163222-33-1/ezetimibe |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Therapy for early reperfusion after stroke.
Next Document: Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an in...